AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16636211 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise therapy (6 months of weekly behavioral therapy for weight loss + exercise training 3 times per week)
Number of subjects: 27
Study 16636211 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise therapy
Number of subjects: 27
Study 15499509 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management programme (DMP) based on weekly telephone monitoring by a case manager
Number of subjects: 115
Study 11092233 — intervention group
Group type: EXPERIMENTAL
Intervention: New weight-reducing agent based on natural ingredients
Number of subjects: 40
Study 11092233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9091835 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaprose S (30 mg tablets, 90 mg daily for 14 days)
Number of subjects: 40
Study 9091835 — intervention group
Group type: COMPARATOR
Intervention: Serratio-peptidase (5 mg tablets, 30 mg daily for 14 days)
Number of subjects: 40
Study 1334101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran (10.3 g beta-glucan/day)
Number of subjects: 36
Study 1334101 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 36
Study 6418295 — intervention group
Group type: COMPARATOR
Intervention: Energy reduced diet (5.1 MJ; 1230 kcal) with unchanged sodium intake (1:ErSn)
Number of subjects: 30
Study 6418295 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and sodium restricted diet (5.1 MJ; 1220 kcal) (2:ErSr)
Number of subjects: 30
Study 29939897 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and apneas (WUAP)
Number of subjects: 9
Study 29939897 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 29939897 — intervention group
Group type: EXPERIMENTAL
Intervention: Apneas only (AP)
Number of subjects: 9
Study 29939897 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up only (WU)
Number of subjects: 9
Study 31607020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral artery stent implantation via radial artery
Number of subjects: 24
Study 31607020 — intervention group
Group type: COMPARATOR
Intervention: Vertebral artery stent implantation via femoral artery
Number of subjects: 24
Study 28646860 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus Social Cognitive Theory (SCT) education
Number of subjects: 65
Study 28646860 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus attention control education
Number of subjects: 65
Study 25647168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a $110 voucher for smoking cessation pharmacotherapy and were registered to an automated calling system.
Number of subjects: 90
Study 25647168 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard care including smoking cessation advice, a brochure, and a prescription for smoking cessation medication if requested.
Number of subjects: 90
Study 24029535 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioural therapy (telephone CBT)
Number of subjects: 99
Study 24029535 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 99
Study 21631542 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin and flumazenil combination
Number of subjects: 60
Study 21631542 — intervention group
Group type: COMPARATOR
Intervention: placebos
Number of subjects: 60
Study 19483295 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine dosage fosinopril (10 mg once daily)
Number of subjects: 35
Study 19483295 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle dosage fosinopril (10 mg twice a day)
Number of subjects: 35
Study 19483295 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study 16920648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 33
Study 16920648 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study 16419683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-frequency masking with the UltraQuiet device
Number of subjects: 15
Study 10639191 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5alpha-reductase inhibitor) for 6 days to 6 years
Number of subjects: 22
Study 10639191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9253234 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data used to build a predictive model based on 21 variables including age, absence of previous similar episodes, weight loss, rectal bleeding, lack of improvement, and presence of a mass on digital rectal examination.
Number of subjects: 336
Study 9253234 — intervention group
Group type: COMPARATOR
Intervention: Clinical data from one subgroup compared with the other subgroup using Bayes' theorem.
Number of subjects: 336
Study 1534881 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look laparoscopy with lysis of adhesions
Number of subjects: 40
Study 1534881 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 40
Study 3896216 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (360 mg/day)
Number of subjects: 18
Study 3896216 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 3064885 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10
Study 3064885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31837959 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (30 mg orally twice per day on days 8-15) combined with 7+3 induction chemotherapy (continuous infusion of cytarabine 100 mg/m2 per day on days 1-7 and intravenous bolus of idarubicin 12 mg/m2 per day on days 1-3)
Number of subjects: 39
Study 31837959 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib maintenance for 12 months
Number of subjects: 39
Study 31837959 — intervention group
Group type: COMPARATOR
Intervention: 7+3 induction chemotherapy (cytarabine and idarubicin)
Number of subjects: 39
Study 29735965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion at bilateral Shenshu (BL23) for 15 min daily, for 4 courses (5 days each with 2 days between courses)
Number of subjects: 60
Study 29735965 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E soft capsules for 28 days
Number of subjects: 60
Study 29735965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 60
Study 28079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine daily oral dose 60-300 mg (3.9-17.6 mg kg-1)
Number of subjects: 180
Study 28079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine daily oral dose 8-10 mg kg-1 day-1 for children <14 kg
Number of subjects: 180
Study 28079918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight as a covariate
Number of subjects: 180
Study 28079918 — intervention group
Group type: EXPERIMENTAL
Intervention: External evaluation of the pharmacokinetic model
Number of subjects: 180
Study 26169067 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Team Facebook app (n=51 individuals, 12 teams)
Number of subjects: 110
Study 26169067 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control condition (n=59 individuals, 13 teams)
Number of subjects: 110
Study 24139461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 24139461 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 21389855 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B12 (0.4 mg)
Number of subjects: 40
Study 21389855 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 (40 mg)
Number of subjects: 40
Study 21389855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellman generator
Number of subjects: 120
Study 18312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Select Sutter generator
Number of subjects: 120
Study 18312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblator generator
Number of subjects: 120
Study 18312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnus generator
Number of subjects: 120
Study 18312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment (all generators)
Number of subjects: 120
Study 16710710 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary job retention vocational rehabilitation programme
Number of subjects: 112
Study 16710710 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 112
Study 16710710 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete sick leave
Number of subjects: 112
Study 16710710 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression score of the hospital anxiety and depression scale
Number of subjects: 112
Study 14748999 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide plus methotrexate
Number of subjects: 40
Study 14748999 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate only (Control)
Number of subjects: 40
Study 10945508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg BID
Number of subjects: 661
Study 10945508 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg TID
Number of subjects: 661
Study 8973979 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (continuous incremental cycling protocol at 55%, 70%, and 85% VO2peak)
Number of subjects: 64
Study 8973979 — intervention group
Group type: EXPERIMENTAL
Intervention: ConA (1.25 micrograms/ml, 2.5 micrograms/ml, and 5.0 micrograms/ml)
Number of subjects: 64
Study 8973979 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (incremental workload)
Number of subjects: 64
Study 8973979 — intervention group
Group type: COMPARATOR
Intervention: Resting and exercise conditions
Number of subjects: 64
Study 1478135 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music therapy provided every day for 8 weeks
Number of subjects: 68
Study 1478135 — intervention group
Group type: COMPARATOR
Intervention: Antidepressive drugs (same for both groups)
Number of subjects: 68
Study 1478135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (active music therapy + antidepressive drugs)
Number of subjects: 68
Study 1478135 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music therapy
Number of subjects: 68
Study 6420374 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-2 units insulin/kg body weight/24 h with feed
Number of subjects: 10
Study 6420374 — intervention group
Group type: COMPARATOR
Intervention: Feed only (no insulin)
Number of subjects: 10
Study 31674267 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE responder index achievement
Number of subjects: 867
Study 31674267 — intervention group
Group type: EXPERIMENTAL
Intervention: New SELENA-SLEDAI flare index flare
Number of subjects: 867
Study 31674267 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in BILAG (constitutional)
Number of subjects: 867
Study 31674267 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in BILAG (musculoskeletal and hematological)
Number of subjects: 867
Study 31674267 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE responder index attainment
Number of subjects: 867
Study 30086681 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70mg
Number of subjects: 955
Study 30086681 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140mg
Number of subjects: 955
Study 30086681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study 26562292 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model-guided (RMG) antiemetic prophylaxis
Number of subjects: 324
Study 26562292 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice (PC) antiemetic therapy
Number of subjects: 324
Study 24375082 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled camel milk (CM) for group I (n = 15)
Number of subjects: 45
Study 24375082 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw camel milk (CM) for group II (n = 15)
Number of subjects: 45
Study 24375082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cow milk) for group III (n = 15)
Number of subjects: 45
Study 22282552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephyr® EBV treatment
Number of subjects: 171
Study 22282552 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 171
Study 20633443 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive rTMS (individual stimuli based on background EEG activity)
Number of subjects: 44
Study 18331610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 12 weeks
Number of subjects: 20
Study 18331610 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 20
Study 15760403 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy (15 mg/m2 biweekly pre-operatively, single dose intra-operatively, total dosage of 300 mg/m2 post-operatively)
Number of subjects: 62
Study 15760403 — intervention group
Group type: COMPARATOR
Intervention: Control group (transplanted only, no chemotherapy)
Number of subjects: 62
Study 11704184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5
Study 9669632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 5 mg three times daily (n = 19)
Number of subjects: 38
Study 8308962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 200
Study 8308962 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 200
Study 2926468 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5-FU administered 24 hours a day for a protracted time (10 weeks or more)
Number of subjects: 179
Study 2926468 — intervention group
Group type: COMPARATOR
Intervention: Daily bolus dose of 5-FU administered intravenously for five consecutive days and repeated at 5-week intervals
Number of subjects: 179
Study 2926468 — intervention group
Group type: COMPARATOR
Intervention: Bolus arm
Number of subjects: 179
Study 2926468 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional arm
Number of subjects: 179
Study 2926468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 179
Study 31563919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided technique
Number of subjects: 66
Study 31563919 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 66
Study 31563919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 66
Study 28000941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 88
Study 28000941 — intervention group
Group type: COMPARATOR
Intervention: Sigmoid resection
Number of subjects: 88
Study 26209642 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 218
Study 26209642 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 218
Study 26209642 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified, but implied as the alternative treatment)
Number of subjects: 218
Study 22552597 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction by leaflet
Number of subjects: 98
Study 22552597 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction supported by demonstration
Number of subjects: 98
Study 22552597 — intervention group
Group type: COMPARATOR
Intervention: Control, no instruction
Number of subjects: 98
Study 22256472 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanol-containing soymilk (2g)
Number of subjects: 120
Study 22256472 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular soymilk)
Number of subjects: 120
Study 19139031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Diane(35)Diario) - 35 microg ethinyl-estradiol plus 2 mg cyproterone acetate
Number of subjects: 40
Study 19139031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin - 850 mg twice daily
Number of subjects: 40
Study 19139031 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-hyperandrogenic women)
Number of subjects: 40
Study 17713165 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous peginterferon alpha-2b and lamivudine (group 1)
Number of subjects: 30
Study 17713165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine started eight weeks before peginterferon (group 2)
Number of subjects: 30
Study 17713165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine started eight weeks after peginterferon (group 3)
Number of subjects: 30
Study 17713165 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at week 104
Number of subjects: 30
Study 17713165 — intervention group
Group type: EXPERIMENTAL
Intervention: At 24 weeks post-treatment
Number of subjects: 30
Study 15126801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once daily
Number of subjects: 103
Study 15126801 — intervention group
Group type: COMPARATOR
Intervention: Medical castration with a luteinizing hormone releasing hormone analogue
Number of subjects: 103
Study 11472703 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stents (SE)
Number of subjects: 1096
Study 9511837 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji III; GIC)
Number of subjects: 166
Study 9511837 — intervention group
Group type: COMPARATOR
Intervention: Light-cured resin-based fissure sealant (Delton; LCR)
Number of subjects: 166
Study 9511837 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GIC to LCR
Number of subjects: 166
Study 8295585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy
Number of subjects: 1500
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop group (received free patient education materials and a 6-hour training workshop)
Number of subjects: 66
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials group (received free patient education materials)
Number of subjects: 66
Study 2926945 — intervention group
Group type: COMPARATOR
Intervention: No-assistance group (received nothing)
Number of subjects: 66
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients asked if they smoked
Number of subjects: 66
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were asked if they smoked
Number of subjects: 66
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were not asked if they smoked
Number of subjects: 66
Study 2926945 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups of physicians
Number of subjects: 66
Study 29650363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (3 preoperative cycles and 3 postoperative cycles of intravenous epirubicin, cisplatin or oxaliplatin, and capecitabine)
Number of subjects: 788
Study 29650363 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (preoperative chemotherapy followed by 45 Gy in 25 fractions of radiotherapy combined with capecitabine and cisplatin)
Number of subjects: 788
Study 28836960 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weekly sessions of psychosocial intervention combined with early palliative care (Arm A)
Number of subjects: 63
Study 28836960 — intervention group
Group type: COMPARATOR
Intervention: Early palliative care only (Arm B)
Number of subjects: 63
Study 28836960 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer treatment (Arm C)
Number of subjects: 63
Study 25454930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) at three different levels
Number of subjects: 0
Study 23915698 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention for adolescents with schizophrenia and their families
Number of subjects: 0
Study 21967361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 0
Study 21967361 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 0
Study 19187375 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal uterine artery Doppler
Number of subjects: 353
Study 19187375 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal umbilical artery Doppler
Number of subjects: 353
Study 19187375 — intervention group
Group type: COMPARATOR
Intervention: Normal umbilical artery Doppler
Number of subjects: 353
Study 16457967 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at skin cancer clinics
Number of subjects: 1041
Study 16457967 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for attendance
Number of subjects: 1041
Study 16457967 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-attendance
Number of subjects: 1041
Study 16457967 — intervention group
Group type: COMPARATOR
Intervention: Future participation plans
Number of subjects: 1041
Study 14977907 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula A (DHA supplemented formula)
Number of subjects: 54
Study 14977907 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula B (DHA unsupplemented formula)
Number of subjects: 54
Study 14977907 — intervention group
Group type: COMPARATOR
Intervention: Control group (human milk)
Number of subjects: 54
Study 11157146 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) followed by mycophenolate mofetil (MMF)
Number of subjects: 13
Study 8893143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 12
Study 8893143 — intervention group
Group type: EXPERIMENTAL
Intervention: Niferex (polysaccharide ferric complex)
Number of subjects: 12
Study 2323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic (gentamicin sulphate)
Number of subjects: 139
Study 2323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiseptic (aluminium acetate)
Number of subjects: 139
Study 223950 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 5 days
Number of subjects: 21
Study 223950 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 10 days
Number of subjects: 21
Study 223950 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy for 15 days
Number of subjects: 21
Study 223950 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy
Number of subjects: 21